Monte Rosa Therapeutics Inc（GLUE）資訊與事件GLUEMonte Rosa Therapeutics Inc

Monte Rosa Doses First Patient in MODeFIRe-1 Study

Monte Rosa Therapeutics announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer with AR mutations. The study follows clinical data previously shared from the Company's Phase 1/2 study of MRT-2359 in combination with enzalutamide in heavily pretreated mCRPC patients. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered and developed by Monte Rosa.

Monte Rosa Therapeutics Activates Phase 2 Trial for MRT-6160

"We're tremendously proud of our progress to date in 2026, defined by strong execution across our clinical-stage portfolio, with two Phase 2 trials activated and additional trials expected across our programs," said Markus Warmuth, Chief Executive Officer of Monte Rosa Therapeutics. "Importantly, for our VAV1 program, Novartis recently activated a Phase 2 study evaluating MRT-6160 in individuals with Sjogren's disease, representing an important step forward for this program and established collaboration. We look forward to additional Phase 2 study activations expected as part of a broader development effort to evaluate the potential of MRT-6160 across other immune-mediated diseases. In addition, the Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations is now activated, and we expect to enroll our first patients imminently, positioning us to validate the strong signals of clinical activity we observed in this patient population in our Phase 1/2 trial. We will update data from the initial Phase 1/2 arm exploring MRT-2359 in advanced CRPC by the end of the year."

Apple Plummets Post-Earnings, Amazon Reports Strong Results

The major averages rallied on the final day of a turbulent month as traders weighed earnings from Apple and Amazon. While Amazon surged on its quarterly beat, Apple suffered a massive decline for their worst post-earnings drop in 13 years. The sharp losses came after the iPhone maker provided a lower-than-expected revenue outlook for Q4 in the face of foreign exchange issues and supply constraints.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applereported better-than-expected Q3 results butfor Q4 revenue growth amid foreign exchange issues and supply constraintsAmazonreported, with AWS net sales rising to $42.23BChevronreported better-than-expected Q2 earnings and revenue, with the company adding that it reportedExxon MobilreportedRedditreportedand provided upbeat Q3 revenue guidance2. WALL STREET CALLS:Benchmark and BTIGRobloxto Sell following quarterly resultsPiper Sandler and Cantor FitzgeraldReplimuneto Overweight following a postive FDA panel vote supporting RP1 approvalArgusBoston Scientificto HoldGuggenheimQuanta Servicesto BuyBMO CapitalNextpowerto Outperform3. AROUND THE WEB:T-Mobileexecutives have told the company's controlling shareholder, Deutsche Telekom, that they no longer support a proposed $300B merger between the two companies, Semafor reportsNXP Semiconductorsis in discussions to acquire Ambarella, FT reportsChimeis planning to cut about 10% of its workforce, or 150 employees, to capitalize on efficiencies created by AI, Bloomberg reportsTSMCis developing advanced AI chip packaging technology, internally called "EMIB-like," that is said to be similar to Intel'sEmbedded Multi-die Interconnect Bridge technique, The Information saysWSJ said some Teslaexecutives have been instructed by Elon Musk to prepare for a separation of the company's China business in the event of a potential merger with SpaceX, though Musk called the report "absurdly fake news."4. MOVERS:Integer Holdingsincreased afterthat KKRis near a deal to take the company privatenVent Electricwas higher in New York afterand listening additional manufacturing space in MinnesotaNewell Brandsand DexComgained in New York afterGoDaddyfell after, providing guidance for Q3, and narrowing its outlook for FY26BioAge Labsand Monte Rosa Therapeuticswere lower after Novo Nordisk'sZEUS triafor IL 6 inhibition5. EARNINGS/GUIDANCE:AbbVie, cut its EPS guidance for FY26, and provided guidance for Q3RBC Bearings, with EPS and revenue beating consensusColgate-Palmolive, with CEO Noel Wallace commenting on "strong broad-based top- and bottom-line results, despite a difficult operating environment"Eaton, provided guidance for Q3, and raised its outlook for FY26Magnaand raised its outlook for FY26INDEXES:The Dow rose 276.97, or 0.53%, to 52,485.03, the Nasdaq gained 251.68, or 1.00%, to 25,373.85, and the S&P 500 advanced 52.09, or 0.70%, to 7,489.72.